Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC)
We will like to thank Topkan and Yildirim [1] for their comments related to our descriptions of the outcome of the randomized phase 3 DAHANCA 10 trial: Effect of darbepoetin alfa and radiotherapy in treatment of squamous cell carcinomas of the head and neck [2]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - September 21, 2018 Category: Radiology Authors: Jens Overgaard, Jan Alsner Tags: Letter to the editor Source Type: research
Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock.
CONCLUSIONS: PCHB was used to stabilize (bridge) a critically ill anemic patient for lifesaving interventions without adverse effects. Additional studies are warranted to explore the drug's safety profile and efficacy in patients declining blood products.
PMID: 30203845 [PubMed - as supplied by publisher] (Source: Transfusion)
Source: Transfusion - September 11, 2018 Category: Hematology Authors: DeSimone RA, Berlin DA, Avecilla ST, Goss CA Tags: Transfusion Source Type: research
Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
ConclusionsThis PMS study showed the safety and effectiveness of long-term use of darbepoetin in a large number of patients. Patients with Hb ≥ 11 g/dL presented fewer composite renal endpoints than those with Hb < 11 g/dL, without an increase in the incidence of cardiovascular-related AEs. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - September 4, 2018 Category: Urology & Nephrology Source Type: research
Effectiveness of darbepoetin alfa in multiple myeloma patients receiving chemotherapy including novel agents.
Conclusion: We demonstrated the efficacy of DA therapy in a homogeneous group of MM patients receiving chemotherapy. DA therapy significantly increased Hb concentration, regardless of baseline Hb level.
PMID: 29963518 [PubMed] (Source: Blood Research)
Source: Blood Research - July 3, 2018 Category: Hematology Tags: Blood Res Source Type: research
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study
Conclusion: A variety of short- and long-acting ESAs are commonly used in European HD facilities to maintain hemoglobin at remarkably similar levels with each ESA type. The availability of numerous ESA options for managing anemia has allowed European providers to optimize anemia management according to the particular circumstances of each patient.Nephron (Source: Nephron)
Source: Nephron - June 26, 2018 Category: Urology & Nephrology Source Type: research
Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP ®
ConclusionLBDE shows high similarity to NESP® with regard to structure and function. (Source: BioDrugs)
Source: BioDrugs - March 19, 2018 Category: Drugs & Pharmacology Source Type: research
A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient
Recombinant human erythropoietin, such as epoetin alfa and darbepoetin alfa, is an important therapy for anemia due to chronic renal failure. Allergy to recombinant human erythropoietin and the need for desens... (Source: Allergy, Asthma and Clinical Immunology)
Source: Allergy, Asthma and Clinical Immunology - March 12, 2018 Category: Allergy & Immunology Authors: Jaime S. Rosa, Van B. Vuong, Orly Haskin and Anne Y. Liu Tags: Case report Source Type: research
The effect of darbepoetin alfa on renal fibrosis in rats with acute unilateral ureteral obstruction.
CONCLUSION: As we know pelvicalyceal ectasia reflects intrapelvic pressure into renal tubular system via renal reflux. Therefore pelvicalyceal ectasia can be used as an indicator of renal tubular pressure. Although as a limitation of our study, renal tubular pressure was not quantitatively evaluated, parallelism between levels of renal ectasia detected in the rats of the sham, and DPO groups can predict that this drug (darbepoetin-a) can decrease renal tubular pressure in acute ureteral obstruction. Moreover, B2 microglobulin levels in the sham, and DPO groups differed from those of ureteral obstruction group, which sugges...
Source: Archivos Espanoles de Urologia - March 11, 2018 Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research
DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group
To evaluate if correction of low hemoglobin (Hb) levels by means of darbepoetin alfa improves the outcomes of radiotherapy in patients with squamous cell carcinoma of the head and neck (HNSCC). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 6, 2018 Category: Radiology Authors: Jens Overgaard, Camilla Molich Hoff, Hanne Sand Hansen, Lena Specht, Marie Overgaard, Pernille Lassen, Elo Andersen, J ørgen Johansen, Lisbeth Juhler Andersen, Jan Folkvard Evensen, Jan Alsner, Cai Grau Tags: Original article Source Type: research
DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
CONCLUSION: Correction of the Hb level with darbepoetin alfa during radiotherapy of patients with HNSCC resulted in a significantly poorer tumor control and survival.
PMID: 29523409 [PubMed - as supplied by publisher] (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - March 6, 2018 Category: Radiology Authors: Overgaard J, Hoff CM, Hansen HS, Specht L, Overgaard M, Lassen P, Andersen E, Johansen J, Andersen LJ, Evensen JF, Alsner J, Grau C Tags: Radiother Oncol Source Type: research
DAHANCA 10 – Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group
To evaluate if correction of low hemoglobin (Hb) levels by means of darbepoetin alfa improves the outcomes of radiotherapy in patients with squamous cell carcinoma of the head and neck (HNSCC). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - March 6, 2018 Category: Radiology Authors: Jens Overgaard, Camilla Molich Hoff, Hanne Sand Hansen, Lena Specht, Marie Overgaard, Pernille Lassen, Elo Andersen, J ørgen Johansen, Lisbeth Juhler Andersen, Jan Folkvard Evensen, Jan Alsner, Cai Grau Tags: Original article Source Type: research
APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania
ConclusionsThe majority of patients were treated according to national and international recommendations. Guideline adherence was associated with more frequent achievement of Hb targets and lower red blood cell transfusion requirements compared with patients starting anemia treatment with darbepoetin alfa at lower-than-recommended Hb levels. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - March 2, 2018 Category: Cancer & Oncology Source Type: research
Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations [Short Communications]
Conclusions:
A poor response to darbepoetin alfa was associated with worse outcomes in heart failure patients with anemia. Patients with a poor response were difficult to identify using clinical and biochemical biomarkers.
Clinical Trial Registration:
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00358215. (Source: Circulation: Heart Failure)
Source: Circulation: Heart Failure - January 24, 2018 Category: Cardiology Authors: van der Meer, P., Grote Beverborg, N., Pfeffer, M. A., Olson, K., Anand, I. S., Westenbrink, B. D., McMurray, J. J. V., Swedberg, K., Young, J. B., Solomon, S. D., van Veldhuisen, D. J. Tags: Clinical Studies, Heart Failure, Mortality/Survival Short Communications Source Type: research
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial
Conclusions: Our analyses provide descriptive insights regarding the temporal changes of Hb, darbepoetin dose, and related parameters as ESRD approaches in participants of TREAT. Hb declined as much as 1 –2 years prior to the development of ESRD, without biochemical evidence of iron deficiency. The most precipitous decline occurred in the months immediately prior to ESRD, despite administration of escalating doses of darbepoetin and in parallel with an increase in CRP.Am J Nephrol 2017;46:488 –497 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 14, 2017 Category: Neurology Source Type: research
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial.
CONCLUSIONS: Our analyses provide descriptive insights regarding the temporal changes of Hb, darbepoetin dose, and related parameters as ESRD approaches in participants of TREAT. Hb declined as much as 1-2 years prior to the development of ESRD, without biochemical evidence of iron deficiency. The most precipitous decline occurred in the months immediately prior to ESRD, despite administration of escalating doses of darbepoetin and in parallel with an increase in CRP.
PMID: 29241199 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - December 14, 2017 Category: Urology & Nephrology Authors: Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P Tags: Am J Nephrol Source Type: research
